Lauren Mays Weddle, PhD | Authors


Transplant Versus Resection for Hepatocellular Carcinoma

July 23, 2015

Although liver transplantation may be a more ideal treatment option compared with resection for many patients with hepatocellular carcinoma (HCC), donor availability remains a major limiting factor to its widespread incorporation.

New Model Improves Liver Function Assessment in HCC

May 16, 2015

A novel, evidence-based model for staging liver function in the setting of hepatocellular carcinoma may offer improved guidance in the selection of appropriate, patient-specific therapeutic strategies.

Evolution of Treatment for HCC: Sorafenib and Beyond

May 08, 2015

The small molecule multikinase inhibitor sorafenib remains the only molecularly targeted therapy approved by the FDA for the treatment of hepatocellular carcinoma, with ongoing clinical trials diligently testing the potential for novel targeted agents or combination therapies to further improve patient outcomes in this setting.